These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37795219)

  • 1. Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.
    Robilotti E; Zeitouni NC; Orloff M
    Front Mol Biosci; 2023; 10():1178382. PubMed ID: 37795219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
    Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers.
    Scanlan H; Coffman Z; Bettencourt J; Shipley T; Bramblett DE
    Front Oncol; 2022; 12():940019. PubMed ID: 35965554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: Oncolytic virotherapy, updates and future directions.
    Fountzilas C; Patel S; Mahalingam D
    Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation of oncolytic viruses in sarcoma.
    Robinson SI; Rochell RE; Penza V; Naik S
    Mol Ther Oncol; 2024 Sep; 32(3):200822. PubMed ID: 39040851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
    Reale A; Calistri A; Altomonte J
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on immunotherapy via oncolytic viruses.
    Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
    Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.
    Kaufman HL; Shalhout SZ; Iodice G
    Front Mol Biosci; 2022; 9():834841. PubMed ID: 35274007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
    Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles.
    Tang G; Wang D; Zhao X; Feng Z; Chen Q; Shen Y
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.